BioGaia AB (FRA:BGLA)
€ 9.115 -0.035 (-0.38%) Market Cap: 931.59 Mil Enterprise Value: 835.03 Mil PE Ratio: 31.83 PB Ratio: 6.64 GF Score: 95/100

Q1 2020 Biogaia AB Earnings Call Transcript

May 07, 2020 / 07:30AM GMT
Release Date Price: €9.01 (-1.31%)
Isabelle Valerie Ghislaine Ducellier;publ;CEO;President
BioGaia AB

()-&

Yes, good morning, everybody, and welcome to BioGaia Interim Management Statement Q1 2020. I hope all of you are doing fine and keeping safe in these difficult circumstances. So today, I'm going to go through our business executive summary, and then Alexander, our BioGaia's CFO, is going to take you through our financials. And as mentioned before, we will take your question at the end of this presentation.

Next page, please. So how did our Q1 look like in a nutshell? So first of all, our sales increased by 7%, which is mainly driven by the sales of our Paediatrics product and mainly thanks to our Protectis drop for babies. Regarding the Adult segment, we have an increase as well. But in that case, it is mainly driven by Protectis tablet and to a certain extent by Gastrics (sic) [Gastrus] tablets.

Regarding the sales per region, we have a very strong sales growth in EMEA, plus 14%; a decrease of sales in APAC, minus 6%; and a slight decrease in Americas with minus 3

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot